DownloadLast Updated: 29 May 2025
Source: Statifacts
The global gastroenterology market size was evaluated at USD 36.44 billion in 2024 and is expected to grow around USD 65.38 billion by 2034, registering a CAGR of 6.01% from 2025 to 2034.
| Industry Worth | Details |
| Market Size in 2025 | USD 38.48 Billion |
| Market Size by 2034 | USD 65.38 Billion |
| Market Growth Rate from 2025 to 2034 | CAGR of 6.01% |
Due to an increasing number of stomach and digestive diseases, the range of access to the gastroenterology market continues to increase significantly. It is critical to point out that this market is not only confined to a gastroenterology service, but also has many gastroenterology products and consumables for patients with stomach problems, ulcers, acid reflux, irritable bowel syndrome (IBS), and Crohn's disease.
Medical innovations in technology have enabled incremental improvements in doctors’ abilities to properly diagnose digestive diseases at much earlier stages, and mental barriers to becoming aware of an issue have been improved by a new push in sharing informational pamphlets and websites for digestion health education. The need for effective care related to digestion is a great situation for expanded investment in health. The demand for effective and efficacious physiological care in conjunction with advancing the diversity of care needs in gastroenterology will aid the gastroenterology market in reaching sustained growth in the near future.
“At a gastroenterology practice, both the physical assessment of patients and filling out progress notes are critical to providing accurate treatments. Sunoh.ai significantly reduces the administrative burden by streamlining clinical documentation at our practice—the provider can see an average of five more patients daily, while still spending 30 minutes on each visit. The quality of notes and accuracy of notes continues to exceed our expectations.”
North America
North America dominated the gastroenterology market in 2024. This is because the U.S. and Canada have a lot of hospitals and clinics that are advanced hospitals and clinics with advanced technology. People in North America consume a lot of fast food and have stressful lifestyles, leading to stomach problems such as acid reflux, irritable bowel syndrome, and Crohn's disease. North America also has a strong insurance system to tackle the high healthcare costs in the region. There are many notable medical companies in the U.S. that aid in the development of new treatments and devices for improved digestive health.
Asia-Pacific
Asia-Pacific is anticipated to be the fastest-growing market in the forecasted period of 2025-2034. Countries like China, India, and Japan are increasing the population of people with digestive issues. New studies show that more people in urban areas are eating more spicy food, junk food, and are stressed, which leads to the prolonged risk of stomach ulcers, constipation, and acid reflux. For rural areas, the risk is poor sanitation and unsafe drinking water, which causes stomach infections when ingested. Meanwhile, increasing healthcare access and spending, population awareness about digestive health, and the opening of new hospitals and clinics faster than before are applicable in the Asia-Pacific market, which affirms why the market is quickly expanding.
The gastroenterology market is highly competitive. Some of the key players in the market are Abbott Laboratories, Johnson & Johnson, AbbVie Inc., Salix Pharmaceuticals, GlaxoSmithKline Plc, ALLERGAN, Takeda Pharmaceutical Company Limited, AstraZeneca, Astellas Pharma US Inc., and Pfizer Inc.
The gastroenterology market is dominated by several companies but the companies that are renowned for their contribution to the market are listed below:
Pfizer Inc. is an American multinational company involved in the development and manufacturing of pharmaceuticals and biotechnology. The company develops and produces vaccines for immunology, oncology, cardiology, endocrinology, and neurology.
Johnson & Johnson is an American multinational pharmaceutical, biotechnology, and medical technologies corporation. The company is involved in producing and developing pharmaceutical prescription drugs and medical devices.
Astellas Pharma US, Inc. is a global life science company that provides transformative therapies in disease areas that include oncology, ophthalmology, urology, immunology, and women's health through research and development and pioneering innovations.
Published by Kesiya Chacko
| Stats ID: | 8353 |
| Format: | Databook |
| Published: | May 2025 |
| Delivery: | Immediate |
Last Updated: 29 May 2025
Source: Statifacts
Last Updated: 29 May 2025
Source: Statifacts
| Subsegment | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 | 2034 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Crohn\'s Disease | 17,885.30 | 18,920.20 | 20,033.90 | 21,233.20 | 22,525.40 | 23,918.80 | 25,422.30 | 27,045.60 | 28,799.70 | 30,696.20 | 32,656.00 |
| Ulcerative Colitis | 9,600.30 | 10,118.00 | 10,673.60 | 11,270.40 | 11,911.80 | 12,601.50 | 13,343.70 | 14,142.80 | 15,003.80 | 15,932.20 | 16,886.20 |
| GERD | 6,075.90 | 6,424.70 | 6,800.00 | 7,203.90 | 7,639.10 | 8,108.20 | 8,614.20 | 9,160.40 | 9,750.30 | 10,388.00 | 11,046.60 |
| IBS | 1,920.10 | 2,023.60 | 2,134.70 | 2,254.10 | 2,382.40 | 2,520.30 | 2,668.70 | 2,828.60 | 3,000.80 | 3,186.40 | 3,377.20 |
| Others | 957.00 | 992.60 | 1,030.20 | 1,069.80 | 1,111.60 | 1,155.70 | 1,202.20 | 1,251.30 | 1,303.00 | 1,357.60 | 1,411.20 |
Last Updated: 29 May 2025
Source: Statifacts
| Stats ID: | 8353 |
| Format: | Databook |
| Published: | May 2025 |
| Delivery: | Immediate |
Actionable Solutions
-Coatings-Market.jpg)
